logo
Plus   Neg
Share
Email

Evotec Forms Breakpoint Therapeutics

Evotec SE (EVTCY.PK) said that it formed Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec's DNA damage response or "DDR" portfolio.

Breakpoint Therapeutics, which aims to accelerate early projects through discovery and pre-clinical development and expect to deliver the first IND-ready drug in 2022, will initially focus on advancing multiple drug discovery programmes initiated at Evotec that address high unmet medical needs of different patient groups.

The early stage funding amounting to 30 million euros will be covered by a consortium led by Medicxi, Taiho Ventures LLC, and Evotec. Evotec will hold below 50% of the company and consolidate at equity accordingly.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Snap Inc. (SNAP) Tuesday reported a narrower loss for the second quarter that also was better than Wall Street's expectations, as revenues surged on strong user growth. The company issued a strong revenue guidance for the current quarter, sending its shares up 10 percent in after-hours trade. California-based... Shares of Texas Instruments Inc. (TXN) gained over 6% in extended trading session on Tuesday after the analog chip maker reported a second-quarter profit and revenue that trumped analysts' expectations. The company also issued a strong financial outlook for the third quarter. Dallas, Texas-based Texas... Justin Sun, the entrepreneur who founded the cryptocurrency platform TRON, has postponed his charity lunch with billionaire investor Warren Buffett due to ill health. "TRON Foundation announces postponement of Warren Buffett lunch, press conferences after founder Justin Sun falls ill with kidney stones....
Follow RTT